BMEA Biomea Fusion, Inc.
Price Chart
Executive Summary
Biomea Fusion announced the first patient dosed in two Phase II trials (COVALENT-211 and COVALENT-212) evaluating icovamenib in type 2 diabetes patients with high unmet need, including insulin-deficient patients and those uncontrolled on GLP-1 therapies. Topline data from both studies are expected in Q4 2026, marking a key clinical milestone in advancing a potential disease-modifying therapy targeting beta-cell dysfunction.
Actionable Insight
Traders should monitor enrollment progress and safety signals ahead of the Q4 2026 topline data readout, which could serve as a major value inflection point. Positive durability data could position icovamenib as a first-in-class disease-modifying therapy in T2D, justifying premium valuation in a high-unmet-need population.
Key Facts
- First patient dosed in COVALENT-211 and COVALENT-212, two Phase II trials of icovamenib in type 2 diabetes.
- COVALENT-211 targets insulin-deficient T2D patients; COVALENT-212 targets T2D patients uncontrolled on GLP-1 receptor agonists.
- Each trial will enroll ~60 patients (2:1 randomization), with primary endpoint at 26 weeks and durability assessed at 52 weeks.
- Topline data expected in Q4 2026.
- Prior Phase II COVALENT-111 data showed up to 1.5% and 1.8% placebo-adjusted HbA1c reductions in these subgroups, sustained for 9 months post-treatment.
Financial Impact
No direct financial impact from this announcement; clinical progress may enhance valuation potential ahead of data readouts.
Risk Factors
- Clinical trial delays or slow enrollment could push back data readouts.
- Phase II results may not replicate prior subgroup findings from COVALENT-111.
- Safety issues could emerge in larger or longer studies.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $1.20 awaiting T+5 | awaiting T+5 | — | $1.17 (−2.50%) |
|
Jun 5, 2026
7d ago
|
Press Release
| $1.29 awaiting T+5 | awaiting T+5 | — | $1.17 (−9.30%) |
|
May 11, 2026
4w ago
|
8-K
| $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $1.17 (−25.95%) |
|
May 11, 2026
4w ago
|
Press Release
| $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $1.17 (−25.95%) |
|
Apr 28, 2026
6w ago
|
8-K
| $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $1.17 (−23.53%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $1.17 (−23.53%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $1.53 $1.76 | ▲ +15.03% | ▲ +11.09% | $1.17 (−23.53%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $1.22 $1.49 | ▲ +22.13% | ▲ +22.37% | $1.17 (−4.10%) |
|
Feb 25, 2026
15w ago
|
8-K
| $1.41 $1.39 | ▼ −1.42% | ▼ −0.32% | $1.17 (−17.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access